Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03239002
Other study ID # 2010_24
Secondary ID 2011-A00105-36
Status Completed
Phase N/A
First received July 31, 2017
Last updated January 29, 2018
Start date July 2011
Est. completion date September 2017

Study information

Verified date January 2018
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is the first study with a real diagnostic and prognostic focus in prenatal. In addition to this innovative aspect, the identification of cryptic imbalances in fetuses with malformative syndrome would be an invaluable resource for the identification of new genes involved in development, as is already the case for postnatal studies.

This research aims to:

1. to test the feasibility of this protocol, ie the practical application of this new technology in the context of prenatal diagnosis,

2. demonstrate and evaluate the possible involvement of cryptic chromosomal abnormalities in fetuses with a thick neck associated with other malformations and recruited on the strict criteria mentioned above,

3. assist in the diagnosis of these fetuses and genetic information for their families,

4. identify new regions of the genome potentially involved in the occurrence of congenital malformations.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date September 2017
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- a karyotype performed from a trophoblast biopsy or an amniotic fluid puncture is normal or apparently balanced.

- The fetuses included in the study should have one of the following two criteria:

- 1) Thick bone (greater than 99th percentile, between week 11 and week 13 of amenorrhoea plus 6 days, correlated to a cranio-caudal length measured between 45 and 84 mm) detected in the first trimester of pregnancy associated with One or more echographic sign (s).

- 2) At least two ultrasound call signs involving the following organs (heart, kidney, brain, limbs, digestive tract, face) or intrauterine growth retardation (less than 3rd percentile) associated with one of these Signs of appeal.

Exclusion Criteria:

- The parturientes in emergency situation,

- Benefiting from a legal protection (guardianship / curatorship)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Hôpital Jeanne de Flandre - CHRU de Lille Lille

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient with Ultrasound call signs (thick neck and / or any other organ concerned) During the first trimester of pregnancy
Secondary CGH-array analysis CGH-array result: normal, deletion or duplication, de novo or inherited, size, type and number of genes involved During the first trimester of pregnancy